Corbus Pharmaceuticals to Showcase Pipeline at Major Healthcare Investor Conferences

Corbus Pharmaceuticals announced that Chief Executive Officer Yuval Cohen will present the company's corporate overview and participate in one-on-one investor meetings at two major healthcare conferences in the coming months. The clinical-stage biopharmaceutical company will participate in the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026, followed by the Jefferies Global Healthcare Conference scheduled for June 2-4, 2026. These investor presentations represent a key opportunity for the company to highlight its pipeline progress and articulate its strategic vision to institutional investors, equity research analysts, and healthcare industry participants.

Pipeline Focus: Two Distinct Therapeutic Approaches

Corbus Pharmaceuticals is developing a diverse pipeline centered on two promising candidates across different therapeutic areas:

• CRB-701: An antibody drug conjugate (ADC) designed to target Nectin-4-expressing tumors, representing the company's oncology focus. ADCs have emerged as a major innovation vector in cancer therapeutics, combining the specificity of monoclonal antibodies with cytotoxic payloads to maximize therapeutic efficacy while limiting off-target toxicity.

• CRB-913: An obesity treatment candidate that positions Corbus Pharmaceuticals within one of the fastest-growing segments of the pharmaceutical market. The obesity and weight-management sector has attracted significant institutional capital following the commercial success of GLP-1 receptor agonists.

The dual focus on oncology and metabolic diseases reflects a broader industry trend toward portfolio diversification, allowing Corbus Pharmaceuticals to capture value across multiple high-growth therapeutic categories. This approach also provides investors with exposure to multiple market tailwinds simultaneously—robust demand for innovative cancer treatments and unprecedented interest in weight-loss therapies.

Market Context: Investor Appetite for Clinical-Stage Innovation

The timing of Corbus Pharmaceuticals' conference participation occurs within a dynamic environment for biotech investor engagement. Healthcare investor conferences serve as critical venues where emerging biopharmaceutical companies can differentiate themselves, provide clinical and preclinical updates, and build relationships with potential funding partners.

The antibody drug conjugate sector has demonstrated significant commercial momentum in recent years, with multiple ADCs achieving blockbuster status and commanding premium valuations. The success of ADC platforms has elevated investor interest in novel oncology approaches, creating favorable conditions for companies like Corbus Pharmaceuticals to attract capital and partnership interest.

Simultaneously, the metabolic disease space—particularly obesity treatments—has become one of the most actively monitored therapeutic areas in healthcare investment. The emergence of highly effective pharmacological interventions has transformed obesity from a lifestyle disease into a legitimate pharmaceutical market opportunity, valued in the hundreds of billions of dollars globally.

Investor Implications: Positioning for Growth and Partnerships

For shareholders and prospective investors, Corbus Pharmaceuticals' participation in these conferences signals management confidence in pipeline progress and readiness to engage with the investment community at a critical juncture. The presentation of a dual-asset pipeline demonstrates a risk-mitigation strategy—if one program faces development headwinds, value can potentially be captured through the alternative program.

Key considerations for investors monitoring Corbus Pharmaceuticals:

• Conference participation typically precedes significant announcements or catalysts, suggesting potential clinical updates or partnership discussions in the near term
• Pipeline stage clarity regarding CRB-701 and CRB-913 development timelines will be crucial for understanding near-term catalysts and value inflection points
• Capital adequacy for funding the clinical development of multiple candidates, particularly critical for clinical-stage companies with limited product revenue
• Competitive positioning within increasingly crowded oncology and obesity treatment landscapes
• Partnership potential with larger pharmaceutical companies or biotech firms seeking to in-license promising assets

For broader market participants, the visibility that Corbus Pharmaceuticals achieves through major investor conferences contributes to market discovery and potential institutional capital flow into the clinical-stage biotechnology sector.

Looking Forward: Catalysts and Development Trajectory

The next several months will prove significant for Corbus Pharmaceuticals as CEO Yuval Cohen takes these presentations to institutional audiences. Investor feedback garnered at the RBC Capital Markets and Jefferies conferences will likely inform the company's capital allocation priorities and strategic partnerships.

For investors tracking the company, these conference presentations provide an opportunity to assess management articulation of the scientific rationale for CRB-701 and CRB-913, competitive differentiation, and pathway to value creation. The clinical-stage biopharmaceutical landscape rewards companies that can clearly communicate both the scientific promise and commercial opportunity of their pipelines—a skill that will be on full display at these major investor forums.

As the healthcare investment community continues to closely monitor innovation in oncology and metabolic disease, Corbus Pharmaceuticals' upcoming presentations will contribute to the broader narrative around emerging therapeutic opportunities and capital allocation within healthcare innovation.